Dramatic leap, part II

Last April, Eisai Co. Ltd. laid out a five-year plan that was focused on moving the company into oncology. At the time, Eisai had small molecule oncology research, but no cancer products on the market. The company checked that box last September, when it

Read the full 443 word article

How to gain access

Continue reading with a
two-week free trial.